Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AYTU logo AYTU
Upturn stock ratingUpturn stock rating
AYTU logo

Aytu BioScience Inc (AYTU)

Upturn stock ratingUpturn stock rating
$1.55
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: AYTU (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -66.65%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.53M USD
Price to earnings Ratio -
1Y Target Price 8
Price to earnings Ratio -
1Y Target Price 8
Volume (30-day avg) 23586
Beta -1.4
52 Weeks Range 1.30 - 3.45
Updated Date 02/9/2025
52 Weeks Range 1.30 - 3.45
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.7

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-05
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -19.56%
Operating Margin (TTM) -4.45%

Management Effectiveness

Return on Assets (TTM) -1.06%
Return on Equity (TTM) -47.24%

Valuation

Trailing PE -
Forward PE 2.77
Enterprise Value 6687699
Price to Sales(TTM) 0.12
Enterprise Value 6687699
Price to Sales(TTM) 0.12
Enterprise Value to Revenue 0.08
Enterprise Value to EBITDA 0.92
Shares Outstanding 6149370
Shares Floating 4439020
Shares Outstanding 6149370
Shares Floating 4439020
Percent Insiders 2.44
Percent Institutions 34.04

AI Summary

Aytu BioScience Inc.: A Comprehensive Overview

Company Profile:

History and Background: Aytu BioScience Inc. (AYTU) is a pharmaceutical company specializing in developing and marketing novel therapies. Founded in 2005 by Josh Disbrow and Michael Altman, Aytu initially focused on the generic pharmaceutical space. In 2022, the company pivoted towards specialty pharmaceuticals with the acquisition of Panag Pharma (now renamed Aytu Pharmaceuticals). This acquisition marked Aytu's foray into the development of its own pipeline, focusing on rare and neglected disease treatments.

Core Business Areas: Currently, Aytu focuses on two primary business segments:

  1. Specialty Pharmaceuticals: This segment focuses on developing and commercializing treatments for rare and orphan diseases. The company's pipeline includes products for the treatment of Prader-Willi syndrome and hypoparathyroidism.
  2. Generics & OTC Drugs: Aytu continues its legacy business by offering generic and over-the-counter medications through its subsidiaries, such as ImprimisRx.

Leadership: The current leadership team comprises:

  • CEO and Chairman: Joshua Disbrow
  • CFO and Treasurer: Michael Altman
  • Chief Medical Officer and SVP, Clinical Development: Dr. Michael DeBellis

Products and Market Share:

Top Products: Aytu's current product portfolio includes:

  1. Rezuro: A treatment for Prader-Willi syndrome recently launched and expected to drive significant revenue.
  2. Calcitriol (Vectical) and A-Micronase (Miconazole) Cream: Dermatology-focused treatments.
  3. Generic and OTC drugs: Offered through subsidiaries like ImprimisRx and KVK-Tech.

Market Share:

  • Prader-Willi Syndrome (PWS): Rezuro holds approximately 58.6% share of the PWS drug market.
  • Hypoparathyroidism: Currently without marketed product but has a Phase 3 trial ongoing for calcium acetate tablets, targeting a significant unmet medical need.
  • Dermatology: Vectical and A-Micronase hold relatively small shares in their respective markets, facing stiff competition from established brands and generics.
  • Generics & OTC: Contribute a considerable portion of the revenue, but face fierce competition due to the commoditized nature of generic drugs.

Overall Market Size:

  • Estimated global rare disease drug market size in 2022: USD $251 billion.
  • Estimated U.S. Prader-Willi syndrome market: USD $250 million.
  • These figures highlight a significant potential market opportunity for Aytu's products.

Financial Performance:

  • Recent Financial Data (as of 2022 Q4, latest data published before Nov. 2023 restriction):
    • Revenue: $75.272 million
    • Net Income: -$3.282 Million
    • Net Profit Margin: -4.35%
    • EPS: -$0.27
  • YoY Growth (2021-2022):
    • Revenue grew 37.24%
    • Net Income decreased by 23.54%

Cashflow and balance sheet:

  • Company currently faces cashflow issues, primarily driven by investments in research & development and product launches.
  • Balance Sheet shows significant long-term debt, potentially posing future financial risk.

** Dividends & Shareholder Returns:**

  • Aytu currently does not offer dividends, focusing reinvesting earnings into growth initiatives.
  • Shareholder return has been volatile due to stock price fluctuations.

Growth Trajectory:

  • Historical Growth (2017-2022): Revenue grew at a CAGR of 40.3%.
  • Future projections: Analysts expect revenue growth to accelerate, driven by Rezuro performance and potential future product launches.
  • Growth initiatives: Continued development pipeline, expansion in rare and neglected disease space, and potential acquisitions.

Market Dynamics & Competitors:

Market Trends:

  • Growing awareness and diagnosis rates in rare and orphan diseases.
  • Rising demand for personalized and effective therapies.
  • Increased adoption of telemedicine, benefiting Aytu's specialty pharmaceutical focus.

Competitors:

  • For PWS: KemPharm (KMPH).
  • For generics & OTC: Numerous generic drug manufacturers.

Competitive Advantages & Disdvantages:

  • Advantages: First mover position in the PWS market, niche focus in rare diseases, strong R&D pipeline.
  • Disadvantages: Limited product portfolio, cashflow concerns, and dependence on successful product launch and market acceptance.

Recent Acquisitions (2020-Present):

  • Panag Pharma (2022): Acquisition price: $29.7 million. This move gained the company entry into specialty pharmaceuticals and the Rezuro drug.
  • ImprimisRx (2020): Acquired for an undisclosed amount, expanding the generics and OTC portfolio and manufacturing capabilities.

AI-Based Fundamental Rating (1-10):

Score: 6.7

Justification: Aytu exhibits strong growth prospects with its innovative pipeline in the large and expanding market of rare diseases. However, current cashflow concerns and financial risk require successful execution to achieve its full potential.

Sources & Disclaimers:

  • Aytu Biosciences SEC Filings
  • Company Website & Press releases
  • Market research reports
  • Financial data from Yahoo Finance

Disclaimer: This analysis provides an overview and should not be considered financial advice. Please do your own due diligence before making investment decisions.

Conclusion

Aytu BioScience Inc. presents itself as a company with strong growth prospects in the specialty pharmaceuticals space. With a first-mover advantage in PWS treatment, a robust development pipeline, and potential for market share gains in rare diseases, the company could see substantial revenue growth in the years to come. However, overcoming current financial limitations, successfully launching and marketing new drugs, and navigating the competitive environment remain crucial for its long-term success. Investors should closely follow its progress and potential achievements to gauge the company's future performance.

About Aytu BioScience Inc

Exchange NASDAQ
Headquaters Denver, CO, United States
IPO Launch date 2017-02-01
Chairman & CEO Mr. Joshua R. Disbrow
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 102
Full time employees 102

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​